Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Dow Jones Industrial Average
) is trading up 13 points at 17,609 as of Tuesday, Jun 30, 2015, 12:36 p.m. ET. During this time, 158.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 341.8 million. The NYSE advances/declines ratio sits at 1,652 issues advancing vs. 1,385 declining with 154 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Holding back the Dow today is
), which is lagging the broader Dow index with a 22-cent decline (-0.7%) bringing the stock to $33.37. Volume for Pfizer currently sits at 14.4 million shares traded vs. an average daily trading volume of 23.6 million shares.
Pfizer has a market cap of $208.87 billion and is part of the health care sector and drugs industry. Shares are up 7.8% year-to-date as of Monday's close. The stock's dividend yield sits at 3.3%.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide.
TheStreet Ratings rates Pfizer as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.
- You can view the full Pfizer Ratings Report.